

#### Evaluation of SMART-Seq® Human BCR (with UMIs) for unbiased BCR repertoire profiling


Shaveta Goyal

**R&D Group Leader, NGS** 



For Research Use Only. Not for use in diagnostic procedures. © 2024 Takara Bio Inc. All rights reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Additional product, intellectual property, and restricted use information is available at takarabio.com.


#### Takara Bio: core capabilities



NGS PCR, qPCR, RT-PCR Cloning Nucleic acid purification Gene delivery Functional genomics Protein expression & purification OEM



### Takara Bio: immune repertoire profiling solutions




- Flexible input range
  - \_ 1 ng-1 μg
- RNA from various sample types
  - B cells/T cells, PBMCs, whole blood, bone marrow, lymph node
- **UMIs** for error correction, confident clonotype calling
- **Sensitivity** to capture low-abundant clonotypes
- Capture all/most isotypes
  - BCR: IgA/D/E/G/M for heavy chain; IgK/L for light chain
  - TCR: TCRα, TCRβ
- Sequencing flexibility
  - Full length (300 x 2 bp)
  - CDR3 only (150 x 2 bp)
- UDIs for **multiplexing** capabilities
  - 384 samples in a single run



# Evaluating bias in BCR repertoire profiling: FDA consortium study design

- The diversity of the BCR repertoire requires accurate analysis for correct biological information
- Bias from the assay (multiplex primers, PCR errors) or sequencing instruments could affect the outcome of immunological studies
- To understand the use of controls to check for such bias, we conducted a study in collaboration with the FDA\*
  - Provided RNA samples from individual cell lines with known clonotype composition
  - Produced spike-in cell line mix using provided RNA samples




\*We would like to thank Wenming Xiao (FDA) for study design input and RNA samples.



#### FDA consortium study design

- Libraries from spike-in cell line mix dilutions were prepared using SMART-Seq Human BCR (with UMIs)
- To assess for bias in sequencing platform, libraries were sequenced on the Illumina® NextSeq® 2000, MiSeq®, NextSeq 2000-XLEAP, and the Element AVITI System\*
- Sequencing data was analyzed using Cogent<sup>™</sup> NGS Immune Profiler


#### SMART-Seq Human BCR (with UMIs) workflow




\*We would like to thank Robin Bombardi (Illumina) for sequencing libraries on Illumina platforms and Element Biosciences for sequencing libraries on the AVITI System.



#### Reproducible performance across a wide input range






SMART-seq Human BCR (with UMIs) performs consistently at low and high inputs.

Clonotype frequencies correlate between technical replicates at low and high inputs.



#### Expression abundance: ddPCR




Prior to producing the spike-in cell line mix, RNA from each individual cell line was analyzed using ddPCR for heavy chain expression (IgG or IgM). JK-6 exhibited the highest expression, followed by WSU-DLCL.



#### Unbiased amplification: spike-in cell line proportions

**Observed cell line proportions** 




Normalized cell line proportions

The normalized, observed spike-in cell line proportions calculated from libraries prepared with SMART-Seq Human BCR (with UMIs) are the same as the expected cell line proportions, demonstrating a lack of amplification bias.



#### Precise quantification of low-abundant clonotypes




The number of UMI groups identified at tested concentrations is dependent on copies of target molecules.

- 25 ng RNA input: R<sup>2</sup> = 0.910– 0.969
- 100 ng RNA input: R<sup>2</sup> = 0.940–
  0.967
- 500 ng RNA input: R<sup>2</sup> = 0.961– 9.974




#### Reproducible detection of low-abundance clonotypes



Libraries prepared with SMART-Seq Human BCR (with UMIs) are sensitive enough to detect lowabundance clonotypes. The limit of detection (LOD) was 1 x  $10^{-6}$  for RNA inputs of 25–100 ng and  $4 \times 10^{-7}$  for an RNA input of 500 ng.




#### Consistency across Illumina sequencers



Libraries produced from 25 ng input with SMART-Seq Human BCR (with UMIs) performed comparably when sequenced on the MiSeq, NextSeq 2000, and NextSeq 2000-XLEAP.



#### Precise quantification of low-abundant clonotypes on the Element AVITI System




Libraries sequenced on the Element AVITI system showed excellent linearity, as UMI groups corresponded to the target molecule copies.

 500 ng RNA input R<sup>2</sup> = 0.952– 0.970



### Detection of low-abundant clonotypes on AVITI



For libraries sequenced on the AVITI System, the limit of detection (LOD) increased with an increase in RNA input, and a reproducible LOD of 4 x 10<sup>-7</sup> was achieved at 500 ng RNA input. These data are comparable to data obtained for libraries sequenced on Illumina platforms.



#### Conclusions

Our data demonstrates that SMART-Seq Human BCR (with UMIs) is:

- Free of bias—the correlation between ddPCR expression data and NGS data shows that SMART-Seq Human BCR (with UMIs) is free from potential biases introduced by PCR, primers, or sequencing instruments
- **Reproducible**—libraries produced with SMART-Seq Human BCR (with UMIs) show high reproducibility between technical replicates
- Accurate—libraries produced with SMART-Seq Human BCR (with UMIs) show linear detection for spike-in clonotypes at various dilutions
- Sensitive—libraries produced with SMART-Seq Human BCR (with UMIs) have a limit of detection for tested spike-in concentrations of ≤10<sup>-6</sup>
- Sequencing platform agnostic—SMART-Seq Human BCR (with UMIs) performs similarly on all tested sequencing platforms





## that's GOOD Science!®